Literature DB >> 11222430

Comparison of St John's Wort and imipramine. Remission is important outcome.

P L Cornwall .   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222430      PMCID: PMC1119696     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  9 in total

1.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Authors:  I M Anderson
Journal:  J Affect Disord       Date:  2000-04       Impact factor: 4.839

2.  Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.

Authors:  M Philipp; R Kohnen; K O Hiller
Journal:  BMJ       Date:  1999-12-11

3.  St. John's wort for depression: a meta-analysis of well-defined clinical trials.

Authors:  H L Kim; J Streltzer; D Goebert
Journal:  J Nerv Ment Dis       Date:  1999-09       Impact factor: 2.254

Review 4.  Partial remission in depressive disorders.

Authors:  P L Cornwall; J Scott
Journal:  Acta Psychiatr Scand       Date:  1997-04       Impact factor: 6.392

5.  Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression.

Authors:  P Bech; P Cialdella; M C Haugh; M A Birkett; A Hours; J P Boissel; G D Tollefson
Journal:  Br J Psychiatry       Date:  2000-05       Impact factor: 9.319

6.  St John's wort for depression--an overview and meta-analysis of randomised clinical trials.

Authors:  K Linde; G Ramirez; C D Mulrow; A Pauls; W Weidenhammer; D Melchart
Journal:  BMJ       Date:  1996-08-03

7.  Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.

Authors:  H Woelk
Journal:  BMJ       Date:  2000-09-02

8.  Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.

Authors:  E Schrader
Journal:  Int Clin Psychopharmacol       Date:  2000-03       Impact factor: 1.659

Review 9.  SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.

Authors:  J M Kent
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.